I saw in FierceBiotech today that Pascal Soriot, CEO of AZN, is rumoured to be leaving AZN for Teva. Interesting to me because of how it might affect what most would think is AZN's natural interest in Apabetalone but also how it might affect Teva's potential interest. I think Teva, the number 1 generic pharma in the world, is also a natural fit for Apabetalone given that Rosuvastatin is now generic. Just some thoughts...